A carregar...
Antibodies to watch in 2015
The commercial pipeline of recombinant antibody therapeutics is robust and dynamic. As of early December 2014, a total of 6 such products (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted first marketing approvals in 2014. As discussed in this perspective on...
Na minha lista:
| Publicado no: | MAbs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622967/ https://ncbi.nlm.nih.gov/pubmed/25484055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/19420862.2015.988944 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|